Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
MeSH Number(s)
C04.557.386.480.150.585
C15.604.515.569.480.150.585
C20.683.515.761.480.150.585
Concept/Terms
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Lymphoma, Large-Cell
- Large-Cell Lymphomas
- Lymphoma, Large Cell
- Lymphomas, Large-Cell
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Large-Cell, Diffuse
- Large-Cell Lymphoma
- Large Cell Lymphoma
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Harvard Catalyst Profiles by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 1 | 2 | 3 |
1996 | 8 | 2 | 10 |
1997 | 6 | 3 | 9 |
1998 | 3 | 2 | 5 |
1999 | 4 | 1 | 5 |
2000 | 3 | 2 | 5 |
2001 | 4 | 2 | 6 |
2002 | 7 | 4 | 11 |
2003 | 7 | 1 | 8 |
2004 | 7 | 1 | 8 |
2005 | 13 | 6 | 19 |
2006 | 17 | 3 | 20 |
2007 | 18 | 5 | 23 |
2008 | 10 | 7 | 17 |
2009 | 13 | 4 | 17 |
2010 | 19 | 3 | 22 |
2011 | 22 | 3 | 25 |
2012 | 19 | 2 | 21 |
2013 | 25 | 2 | 27 |
2014 | 26 | 2 | 28 |
2015 | 34 | 2 | 36 |
2016 | 28 | 5 | 33 |
2017 | 22 | 2 | 24 |
2018 | 25 | 1 | 26 |
2019 | 32 | 1 | 33 |
2020 | 38 | 3 | 41 |
2021 | 43 | 0 | 43 |
2022 | 41 | 0 | 41 |
2023 | 49 | 0 | 49 |
2024 | 9 | 0 | 9 |
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood. 2024 Feb 01; 143(5):404-416.
-
Two years later: CD19 CAR-T going the distance. Blood. 2024 Feb 01; 143(5):379-380.
-
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024 01 23; 8(2):484-496.
-
Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma. Cell Mol Life Sci. 2024 Jan 10; 81(1):21.
-
The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024 03; 262(3):255-270.
-
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024 Mar; 59(3):366-372.
-
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax. Haematologica. 2024 Jan 01; 109(1):186-199.
-
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023 12 28; 142(26):2327-2331.